These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
245 related articles for article (PubMed ID: 16734133)
1. Role of increased transforming growth factor beta protein expression in the pathogenesis of Peyronie's disease. Hassoba H; El-Sakka A; Lue T Egypt J Immunol; 2005; 12(1):1-8. PubMed ID: 16734133 [TBL] [Abstract][Full Text] [Related]
2. Peyronie's disease is associated with an increase in transforming growth factor-beta protein expression. El-Sakka AI; Hassoba HM; Pillarisetty RJ; Dahiya R; Lue TF J Urol; 1997 Oct; 158(4):1391-4. PubMed ID: 9302128 [TBL] [Abstract][Full Text] [Related]
3. The effect of surgical trauma on rat tunica albuginea. El-Sakka AI; Selph CA; Yen TS; Dahiya R; Lue TF J Urol; 1998 May; 159(5):1700-7. PubMed ID: 9554397 [TBL] [Abstract][Full Text] [Related]
4. An animal model of Peyronie's-like condition associated with an increase of transforming growth factor beta mRNA and protein expression. El-Sakka AI; Hassoba HM; Chui RM; Bhatnagar RS; Dahiya R; Lue TF J Urol; 1997 Dec; 158(6):2284-90. PubMed ID: 9366377 [TBL] [Abstract][Full Text] [Related]
5. Alterations in the transforming growth factor (TGF)-beta pathway as a potential factor in the pathogenesis of Peyronie's disease. Haag SM; Hauck EW; Szardening-Kirchner C; Diemer T; Cha ES; Weidner W; Eickelberg O Eur Urol; 2007 Jan; 51(1):255-61. PubMed ID: 16782264 [TBL] [Abstract][Full Text] [Related]
6. Evaluation of nitric oxide synthase and arginase in the induction of a Peyronie's-like condition in the rat. Bivalacqua TJ; Champion HC; Leungwattanakij S; Yang DY; Hyun JS; Abdel-Mageed AB; Sikka SC; Kadowitz PJ; Hellstrom WJ J Androl; 2001; 22(3):497-506. PubMed ID: 11330651 [TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor (TGF)-β type I receptor kinase (ALK5) inhibitor alleviates profibrotic TGF-β1 responses in fibroblasts derived from Peyronie's plaque. Piao S; Choi MJ; Tumurbaatar M; Kim WJ; Jin HR; Shin SH; Tuvshintur B; Yin GN; Song JS; Kwon MH; Lee SJ; Han JY; Kim SJ; Ryu JK; Suh JK J Sex Med; 2010 Oct; 7(10):3385-95. PubMed ID: 20233292 [TBL] [Abstract][Full Text] [Related]
8. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. Bivalacqua TJ; Diner EK; Novak TE; Vohra Y; Sikka SC; Champion HC; Kadowitz PJ; Hellstrom WJ J Urol; 2000 Jun; 163(6):1992-8. PubMed ID: 10799245 [TBL] [Abstract][Full Text] [Related]
9. Reduction in Peyronie's-like plaque size using a vacuum erection device in a rat model of Peyronie's disease via the TGF-β/SMAD signalling pathway. Li J; Wang S; Qin F; Zhu M; You X; Wu C; Fu F; Yuan J Andrologia; 2018 Sep; 50(7):e13051. PubMed ID: 29806152 [TBL] [Abstract][Full Text] [Related]
10. The effects of colchicine on a Peyronie's-like condition in an animal model. El-Sakka AI; Bakircioglu ME; Bhatnagar RS; Yen TS; Dahiya R; Lue TF J Urol; 1999 Jun; 161(6):1980-3. PubMed ID: 10332485 [TBL] [Abstract][Full Text] [Related]
11. Histological and ultrastructural alterations in an animal model of Peyronie's disease. El-Sakka AI; Hassan MU; Nunes L; Bhatnagar RS; Yen TS; Lue TF Br J Urol; 1998 Mar; 81(3):445-52. PubMed ID: 9523668 [TBL] [Abstract][Full Text] [Related]
12. Repeated intratunical injection of adenovirus expressing transforming growth factor-beta1 in a rat induces penile curvature with tunical fibrotic plaque: a useful model for the study of Peyronie's disease. Piao S; Ryu JK; Shin HY; Zhang L; Song SU; Han JY; Park SH; Kim JM; Kim IH; Kim SJ; Suh JK Int J Androl; 2008 Jun; 31(3):346-53. PubMed ID: 17651407 [TBL] [Abstract][Full Text] [Related]
13. Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease. Davila HH; Ferrini MG; Rajfer J; Gonzalez-Cadavid NF BJU Int; 2003 Jun; 91(9):830-8. PubMed ID: 12780843 [TBL] [Abstract][Full Text] [Related]
14. Comparison of apoptotic gene expression profiles between Peyronie's disease plaque and tunica albuginea. Zorba OU; Sirma S; Ozgon G; Salabas E; Ozbek U; Kadioglu A Adv Clin Exp Med; 2012; 21(5):607-14. PubMed ID: 23356197 [TBL] [Abstract][Full Text] [Related]
15. Study of the changes in collagen of the tunica albuginea in venogenic impotence and Peyronie's disease. Chiang PH; Chiang CP; Shen MR; Huang CH; Wang CJ; Huang IY; Shieh TY Eur Urol; 1992; 21(1):48-51. PubMed ID: 1606983 [TBL] [Abstract][Full Text] [Related]
16. Microstructural disorders of tunica albuginea in patients affected by Peyronie's disease with or without erection dysfunction. Iacono F; Barra S; De Rosa G; Boscaino A; Lotti T J Urol; 1993 Dec; 150(6):1806-9. PubMed ID: 8230510 [TBL] [Abstract][Full Text] [Related]
17. Experimental models of Peyronie's disease. Implications for new therapies. Gonzalez-Cadavid NF; Rajfer J J Sex Med; 2009 Feb; 6(2):303-13. PubMed ID: 19138365 [TBL] [Abstract][Full Text] [Related]
18. Prospective analysis of single nucleotide polymorphisms of the transforming growth factor beta-1 gene in Peyronie's disease. Hauck EW; Hauptmann A; Schmelz HU; Bein G; Weidner W; Hackstein H J Urol; 2003 Jan; 169(1):369-72. PubMed ID: 12478192 [TBL] [Abstract][Full Text] [Related]
19. Effect of transdermal electromotive drug therapy on fibrogenic cytokine expression in Peyronie's disease. Stancik I; Schäfer R; Andrukhova O; Oeser R; Plas E; Pflüger H Urology; 2009 Sep; 74(3):566-70. PubMed ID: 19604562 [TBL] [Abstract][Full Text] [Related]
20. Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease. Gokce A; Abd Elmageed ZY; Lasker GF; Bouljihad M; Kim H; Trost LW; Kadowitz PJ; Abdel-Mageed AB; Sikka SC; Hellstrom WJ Andrology; 2014 Mar; 2(2):244-51. PubMed ID: 24574095 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]